Next Treatments
Back to Eczema

AK120

TypeInjection StagePhase 2 Latest updateSep 11, 2025Phase 2 study completed

What stands out

  • Injection every week, 2 or 3 weeks in trials
Derived from NCT06756126 · NCT06035354 · This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Jun 15, 2020. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Sep 11, 2025Phase 2 trial completedA Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06700499
  • Jul 31, 2025Phase 2 main data collectedA Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06700499
  • Jan 1, 2025Phase 2 trial postedA Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) ClinicalTrials.gov NCT06756126
  • Nov 13, 2024Phase 2 trial completedA Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06092762
  • Jul 8, 2024Phase 2 trial startedA Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06700499
  • Jun 21, 2024Phase 1/2 trial completedA Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT06035354
  • Apr 25, 2024Phase 3 trial posted · Status not confirmed by the sponsorA Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06383468
  • Nov 6, 2023Phase 2 trial startedA Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06092762
  • May 17, 2023Trial stopped earlyReason: Clinical study and development strategy adjustment. ClinicalTrials.gov NCT05048056
  • Nov 3, 2021Phase 1/2 trial startedA Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis ClinicalTrials.gov NCT06035354
  • Oct 29, 2021Phase 1 trial completed · Purpose listed as otherA Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis ClinicalTrials.gov NCT04256174
  • Jun 15, 2020Phase 1 trial started · Purpose listed as otherA Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis ClinicalTrials.gov NCT04256174

Sources

Trials